Research and development partnership to accelerate the development of novel therapies
The BIH, the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) and the Charité – Universitätsmedizin Berlin, and Sanofi, Germany GmbH signed a joint research framework agreement in Berlin on October 4, 2017. In the future, the institutions will work together closely on the development of novel therapies for various diseases. In addition, the partners will support talented young researchers and projects with economic and medical potential.
“We are pleased to extend the existing collaboration between Charité and Sanofi in Germany to BIH and MDC with the new contract. By bundling the competencies of all partners, we expect faster progress in development,” said Dr. Rolf Zettl, Administrative Director at the BIH and responsible for Berlin Health Innovations, the joint technology transfer unit of BIH and Charité, at the signing ceremony. “The aim is to ensure that research findings reach patients quickly.”
“The framework agreement with these excellent research institutions is a very important milestone for our German research and development hub leading to a sustainable collaboration with global Sanofi research groups,” said Professor Jochen Maas, General Manager R&D Germany at Sanofi.
Over the next three years, the partners will jointly define scientific challenges and work together in projects extending to early research phases with collaborations beginning in the laboratory. This will enable researchers to identify the development and market potential of research projects more quickly and help promote and accelerate their development.
First joint activities focus on autoimmune diseases and current research activities of Charité and MDC. The partners will evaluate project ideas and pursue joint further development.